339 related articles for article (PubMed ID: 19754386)
81. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.
Poeckel D; Funk CD
Cardiovasc Res; 2010 May; 86(2):243-53. PubMed ID: 20093252
[TBL] [Abstract][Full Text] [Related]
82. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
[TBL] [Abstract][Full Text] [Related]
83. [Leukotrienes: potential therapeutic targets in cardiovascular diseases].
Bäck M
Bull Acad Natl Med; 2006 Oct; 190(7):1511-8; discussion 1518-21. PubMed ID: 17450683
[TBL] [Abstract][Full Text] [Related]
84. Enzymes involved in the conversion of arachidonic acid to eicosanoids in the skin of atopic dogs.
Schlotter YM; Riemers FM; Rutten VP; Knol EF; Willemse T
Exp Dermatol; 2010 Aug; 19(8):e317-9. PubMed ID: 20201960
[TBL] [Abstract][Full Text] [Related]
85. Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP.
Klegeris A; McGeer PL
J Leukoc Biol; 2003 Mar; 73(3):369-78. PubMed ID: 12629151
[TBL] [Abstract][Full Text] [Related]
86. Effects of the 5-lipoxygenase activating protein inhibitor MK886 on voltage-gated and Ca2+-activated K+ currents in rat arterial myocytes.
Smirnov SV; Knock GA; Aaronson PI
Br J Pharmacol; 1998 Jun; 124(3):572-8. PubMed ID: 9647483
[TBL] [Abstract][Full Text] [Related]
87. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways.
Meirer K; Steinhilber D; Proschak E
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):83-91. PubMed ID: 24015667
[TBL] [Abstract][Full Text] [Related]
88. Lipoxygenase inhibitors from natural plant sources. Part 2: medicinal plants with inhibitory activity on arachidonate 12-lipoxygenase, 15-lipoxygenase and leukotriene receptor antagonists.
Schneider I; Bucar F
Phytother Res; 2005 Apr; 19(4):263-72. PubMed ID: 16041764
[TBL] [Abstract][Full Text] [Related]
89. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes.
Di Gennaro A; Carnini C; Buccellati C; Ballerio R; Zarini S; Fumagalli F; Viappiani S; Librizzi L; Hernandez A; Murphy RC; Constantin G; De Curtis M; Folco G; Sala A
FASEB J; 2004 May; 18(7):842-4. PubMed ID: 15001558
[TBL] [Abstract][Full Text] [Related]
90. Extending the understanding of leukotrienes in asthma.
Coffey M; Peters-Golden M
Curr Opin Allergy Clin Immunol; 2003 Feb; 3(1):57-63. PubMed ID: 12582316
[TBL] [Abstract][Full Text] [Related]
91. Genetic determinants of 5-lipoxygenase pathway in a Spanish population and their relationship with cardiovascular risk.
Camacho M; Martinez-Perez A; Buil A; Siguero L; Alcolea S; López S; Fontcuberta J; Souto JC; Vila L; Soria JM
Atherosclerosis; 2012 Sep; 224(1):129-35. PubMed ID: 22835628
[TBL] [Abstract][Full Text] [Related]
92. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW
Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602
[TBL] [Abstract][Full Text] [Related]
93. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments.
Hicks A; Monkarsh SP; Hoffman AF; Goodnow R
Expert Opin Investig Drugs; 2007 Dec; 16(12):1909-20. PubMed ID: 18042000
[TBL] [Abstract][Full Text] [Related]
94. 5-Lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells.
Lötzer K; Jahn S; Kramer C; Hildner M; Nüsing R; Funk CD; Habenicht AJ
Prostaglandins Other Lipid Mediat; 2007 Nov; 84(3-4):108-15. PubMed ID: 17991613
[TBL] [Abstract][Full Text] [Related]
95. 5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B(4) induces degranulation.
Iikura M; Suzukawa M; Yamaguchi M; Sekiya T; Komiya A; Yoshimura-Uchiyama C; Nagase H; Matsushima K; Yamamoto K; Hirai K
J Allergy Clin Immunol; 2005 Sep; 116(3):578-85. PubMed ID: 16159627
[TBL] [Abstract][Full Text] [Related]
96. Targeting leukotrienes for the treatment of COPD?
Drakatos P; Lykouras D; Sampsonas F; Karkoulias K; Spiropoulos K
Inflamm Allergy Drug Targets; 2009 Sep; 8(4):297-306. PubMed ID: 19754414
[TBL] [Abstract][Full Text] [Related]
97. Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Yang LX; Heng XH; Guo RW; Si YK; Qi F; Zhou XB
J Cardiovasc Pharmacol; 2013 Aug; 62(2):205-11. PubMed ID: 23615158
[TBL] [Abstract][Full Text] [Related]
98. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus.
Houard X; Ollivier V; Louedec L; Michel JB; Bäck M
FASEB J; 2009 May; 23(5):1376-83. PubMed ID: 19136615
[TBL] [Abstract][Full Text] [Related]
99. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
Rao TS; Yu SS; Djuric SW; Isakson PC
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):213-28. PubMed ID: 7812673
[TBL] [Abstract][Full Text] [Related]
100. Inhibition of leukotriene production by inhibitors of lipoxygenation.
Garland LG; Hodgson ST
Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():33-48. PubMed ID: 7771347
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
